Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Status:
Recruiting
Trial end date:
2023-02-06
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS)
intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with
invasive aspergillosis (IA).